| Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer M Kohli, W Tan, T Zheng, A Wang, C Montesinos, C Wong, P Du, S Jia, ... EBioMedicine 54, 2020 | 86 | 2020 |
| Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multianalyte liquid biopsy assay for metastatic prostate cancer H Fettke, EM Kwan, MM Docanto, P Bukczynska, N Ng, LJK Graham, ... European urology 78 (2), 173-180, 2020 | 54 | 2020 |
| Expression of androgen receptor splice variant 7 or 9 in whole blood does not predict response to androgen-axis–targeting agents in metastatic castration-resistant prostate cancer SQ To, EM Kwan, HC Fettke, A Mant, MM Docanto, L Martelotto, ... European urology 73 (6), 818-821, 2018 | 44 | 2018 |
| Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial EM Kwan, L Spain, A Anton, CL Gan, L Garrett, D Chang, E Liow, ... European urology 81 (3), 253-262, 2022 | 43 | 2022 |
| Cell-free DNA in cancer: current insights H Fettke, EM Kwan, AA Azad Cellular Oncology 42, 13-28, 2019 | 40 | 2019 |
| Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase HM Lin, B Mak, N Yeung, K Huynh, TG Meikle, NA Mellett, EM Kwan, ... EBioMedicine 72, 2021 | 24 | 2021 |
| Plasma cell–free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer EM Kwan, C Dai, H Fettke, C Hauser, MM Docanto, P Bukczynska, N Ng, ... JCO Precision Oncology 5, 622-637, 2021 | 24 | 2021 |
| Prognostic utility of a whole-blood androgen receptor-based gene signature in metastatic castration-resistant prostate cancer EM Kwan, H Fettke, MM Docanto, SQ To, P Bukczynska, A Mant, D Pook, ... European Urology Focus 7 (1), 63-70, 2021 | 16 | 2021 |
| AlphaBet: combination of radium-223 and [177Lu] Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol) L Kostos, JP Buteau, T Yeung, JD Iulio, J Xie, A Cardin, KY Chin, ... Frontiers in medicine 9, 3449, 2022 | 14 | 2022 |
| Prognostic impact of total plasma cell-free DNA concentration in androgen receptor pathway inhibitor–treated metastatic castration-resistant prostate cancer H Fettke, EM Kwan, P Bukczynska, N Ng, T Nguyen-Dumont, MC Southey, ... European Urology Focus 7 (6), 1287-1291, 2021 | 14 | 2021 |
| Carbamazepine induces focused T Cell responses in resolved Stevens-Johnson syndrome and toxic epidermal necrolysis cases but does not perturb the immunopeptidome for T Cell … NA Mifsud, PT Illing, JW Lai, H Fettke, L Hensen, Z Huang, J Rossjohn, ... Frontiers in Immunology 12, 653710, 2021 | 14 | 2021 |
| Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer B Mak, HM Lin, EM Kwan, H Fettke, B Tran, ID Davis, K Mahon, ... BMC medicine 20 (1), 112, 2022 | 10 | 2022 |
| VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. JP Buteau, LK Kostos, R Alipour, P Jackson, L McIntosh, B Emmerson, ... Journal of Clinical Oncology 41 (6_suppl), TPS281-TPS281, 2023 | 7 | 2023 |
| LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer … LK Kostos, JP Buteau, G Kong, T Yeung, J Di Iulio, MT Fahey, H Fettke, ... Journal of Clinical Oncology 41 (6_suppl), TPS278-TPS278, 2023 | 5 | 2023 |
| Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer (vol 54 … M Kohli, W Tan, T Zheng, A Wang, C Montesinos, C Wong, P Du, S Jia, ... EBIOMEDICINE 66, 2021 | 5 | 2021 |
| BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype H Fettke, C Dai, EM Kwan, T Zheng, P Du, N Ng, P Bukczynska, ... EBioMedicine 95, 2023 | 4 | 2023 |
| Independent prognostic impact of plasma NCOA2 alterations in metastatic castration‐resistant prostate cancer H Fettke, EM Kwan, P Bukczynska, JA Steen, M Docanto, N Ng, P Parente, ... The Prostate 81 (13), 992-1001, 2021 | 4 | 2021 |
| Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay H Fettke, JA Steen, EM Kwan, P Bukczynska, S Keerthikumar, D Goode, ... BioTechniques 69 (2), 133-140, 2020 | 4 | 2020 |
| Circulating tumor DNA and outcomes with lutetium-PSMA in advanced prostate cancer: preliminary results from an Australian study H Fettke, N Ng, C Hauser, P Bukczynska, E Medhurst, L Kostos, J Buteau, ... Cancer Research 82 (12_Supplement), 532-532, 2022 | 3 | 2022 |
| The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug‐reactive T cells in resolved hypersensitivity cases and drug‐naïve healthy donors NA Mifsud, PT Illing, R Ho, JE Tuomisto, H Fettke, KA Mullan, ... Allergy 78 (11), 2980-2993, 2023 | 2 | 2023 |
